Ocular Therapeutix (NASDAQ:OCUL) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Ocular Therapeutix (NASDAQ:OCUL) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05, FiscalAI reports. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. The firm had revenue of $13.25 million during the quarter. During the same quarter in the previous year, the business earned ($0.29) EPS. Ocular Therapeutix’s revenue for the quarter was down 22.4% on a year-over-year basis.

Ocular Therapeutix Stock Up 7.2%

NASDAQ:OCUL traded up $0.62 during mid-day trading on Thursday, reaching $9.17. The stock had a trading volume of 5,738,135 shares, compared to its average volume of 5,361,649. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. The stock’s 50 day simple moving average is $11.94 and its two-hundred day simple moving average is $11.97. Ocular Therapeutix has a 1-year low of $5.78 and a 1-year high of $16.44. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -6.39 and a beta of 0.90.

Analyst Upgrades and Downgrades

OCUL has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Chardan Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price target on shares of Ocular Therapeutix in a research note on Monday, December 8th. TD Cowen restated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Q4 EPS slightly beat estimates — OCUL reported a loss of $0.29 per share vs. consensus near -$0.34 (a small upside vs. forecasts). That EPS beat is a near-term positive signal for investors focused on profitability trajectory. Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
• Positive Sentiment: Analyst sentiment remains constructive — multiple firms maintain Buy/Outperform ratings and the consensus price target (~$22.56) sits well above the current share price, providing upside expectations that can support the stock. MarketBeat OCUL Coverage
• Neutral Sentiment: Company press release / business highlights — management issued a full Q4 & full-year 2025 release summarizing operations and business milestones; these provide context but contain mixed metrics (see link). Ocular Therapeutix: Q4 Earnings Snapshot
• Negative Sentiment: Revenue decline and profitability metrics are weak — Q4 revenue was $13.25M, down ~22% YoY, and the company reported very negative net margin and ROE figures; Zacks flagged a revenue miss. These top-line pressures are a clear downside risk to the stock. Zacks: OCUL Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Insider selling by the COO — Donald Notman sold roughly 11.5k shares across Feb. 2 and Feb. 4 (SEC filings). Repeated insider sales can be interpreted negatively by some investors even if they may be routine. Donald Notman Sells Shares (InsiderTrades)
• Negative Sentiment: Unusual options activity — traders purchased ~25,044 put options on OCUL (a ~473% increase vs. average), signaling elevated bearish/speculative positioning that can amplify downside volatility. (No article link)

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, COO Donald Notman sold 6,035 shares of Ocular Therapeutix stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $8.54, for a total value of $51,538.90. Following the completion of the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at $3,226,429.08. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OCUL. Nisa Investment Advisors LLC boosted its stake in Ocular Therapeutix by 62.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,392 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 893 shares during the period. KBC Group NV acquired a new stake in shares of Ocular Therapeutix in the fourth quarter valued at $78,000. Quarry LP acquired a new stake in Ocular Therapeutix in the 3rd quarter valued at about $80,000. Finally, Trust Co. of Vermont lifted its stake in Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,750 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.